Develops immunotherapies for cancer and infectious diseases. Utilizes proprietary mRNA technology to create targeted treatments. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 38% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Business Quality: Profit power and business quality trail similar companies in the sector.
An investor who bought at the very peak is down 73% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $3.2B a year; the problem isn’t sales — it’s costs running above that number.
There is $17.2B in the vault; even if every debt were paid off, $16.9B would remain.
A loss of $1.3B against $3.2B in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 27/100.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 38/100.
On our five-subject report card, BNTX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: BNTX’s sales are going backwards, and it closed last year at a loss. The road back runs through both.
Not covered, because the filings we hold do not carry it: the revenue breakdown.